Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...

Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Note :Financial Information is based on numbers. Note :Financial Information is based on numbers. Note :Financial Information is based on numbers. Note :Financial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: March 13 at 5:44:21 PM EDT Loading Chart for SNY ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 12,867.55 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...